Blog
    Regulatory UpdateFor PhysiciansApril 4, 2026

    FDA peptide status and safety updates for March 2026

    Review the latest FDA Category 2 listings for BPC-157 and TB-500, plus emerging safety signals for semaglutide including NAION and pulmonary aspiration.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    What are the current FDA regulatory statuses, compounding eligibility, and safety signals for clinical peptides as of March 2026?

    Evidence Snapshot

    • Regulatory Listings: 10 peptides evaluated across FDA Category 2 (503A/503B) and international approval databases.
    • Safety Signals: 10 discrete adverse event signals identified via FAERS and postmarketing surveillance.
    • Clinical Trials: Data from 10 clinical trials including Phase II/III obesity, CV outcomes, and sepsis studies.
    • Warning Letters: Multiple 2020 warning letters (e.g., Tailor Made Compounding) regarding non-approved substance distribution.

    What the Research Shows

    Regulatory and Compounding Status

    As of March 2026, several widely discussed peptides remain non-FDA-approved and are subject to significant regulatory restrictions. BPC-157 is currently listed as a Category 2 bulk substance under 503A, indicating it carries significant safety risks and is ineligible for routine compounding. Specifically, the FDA cites immunogenicity concerns and a lack of safety data for BPC-157.

    Similarly, TB-500 (Thymosin Beta-4) is listed under Category 2 due to immunogenicity risks and a total absence of human exposure data. GHK-Cu, GHRP-2, and Ipamorelin are also classified under Category 2 (503B) by the FDA, with immunogenicity being a primary concern for their exclusion from bulk compounding lists.

    Several peptides recently underwent status changes. Under the interim policy updated in September 2024, nominations for AOD-9604, CJC-1295, Selank, and Ipamorelin were withdrawn or removed. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved and was removed from Category 2 pending advisory review in September 2024, though it remains a substance of concern.

    Safety and Adverse Event Signals

    Safety signals for approved and experimental peptides highlight both gastrointestinal and systemic risks. Semaglutide has a strong signal strength for nausea, vomiting, and delayed gastric emptying, which are included in Section 6 and Section 5.10 of its label. Emerging signals for semaglutide include postmarketing additions for intestinal obstruction (ileus) and pulmonary aspiration, the latter of which was added to the Ozempic label in 2025 due to risks during general anesthesia.

    A significant emerging signal for semaglutide is Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024. This led to a formal European Medicines Agency (EMA) review in January 2025. Additionally, the FDA requires monitoring for suicidal ideation, although current data do not support a risk higher than the background rate.

    Clinical Outcomes and Trial Results

    In obesity trials, semaglutide (STEP 1) demonstrated 14.9% weight loss, while tirzepatide (SURMOUNT-1) showed 22.5% weight loss. A head-to-head trial (SURMOUNT-5) indicated tirzepatide superiority over semaglutide for weight loss. Retatrutide showed 24.2% weight loss at a 12mg dose in Phase II data. Conversely, a Phase III trial for Thymosin Alpha-1 in sepsis (NCT02867267) was negative, showing no reduction in mortality.

    Mechanism

    The provided data does not contain expanded biochemical mechanism-of-action descriptions for these peptides, beyond identifying specific clinical concerns such as immunogenicity for BPC-157, TB-500, and GHRP-2, and delayed gastric emptying as a contributing factor to pulmonary aspiration risk for semaglutide.

    Limitations of the Evidence

    A primary limitation is the total absence of human exposure data for certain peptides like TB-500, and a general lack of safety data for BPC-157. For many substances currently in Category 2, the FDA explicitly cites these data gaps as the basis for their restriction.

    Furthermore, while products like Selank and Semax are approved for use in Russia (the latter for stroke), they lack local FDA evaluation or approval. The safety signals for NAION and pulmonary aspiration are emerging, and definitive causality or large-scale incidence rates are still under formal review (EMA) or recently added to labels (FDA).

    Clinical Takeaway

    The regulatory landscape for peptides remains restrictive, with many substances (BPC-157, TB-500, GHK-Cu) categorized as significant safety risks due to immunogenicity concerns. While GLP-1 and dual/triple-agonist peptides show significant clinical efficacy in weight loss and CV outcomes, they are associated with strong gastrointestinal safety signals and emerging risks such as NAION and pulmonary aspiration.

    Sources

    • REGULATORY STATUS RECORDS: IDs 0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b.
    • FAERS SAFETY SIGNALS: IDs 502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa.
    • CLINICAL TRIAL RECORDS: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, STAY Trial, NCT02867267, NCT068211.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1retatrutide

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.